The US Food and Drug Administration Allergenic Products Advisory Committee this week held a meeting to discuss whether efficacy and safety data support licensure of Palforzia as a treatment to reduce the incidence and severity of allergic reactions, including anaphylaxis, after accidental exposure to peanut in patients four through 17 years of age with a confirmed diagnosis of peanut allergy.
Aimmune Therapeutics is a biopharmaceutical company developing oral treatments for potentially life-threatening food allergies.
The company's Characterized Oral Desensitization ImmunoTherapy (CODIT) approach is intended to provide meaningful levels of protection against allergic reactions resulting from exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens.
Aimmune's first, investigational, complex biologic product candidate, Palforzia (AR101), is being developed as a treatment to reduce the frequency and severity of adverse events following exposure to peanut.
The BLA for Palforzia is under review by the FDA, which granted Palforzia Breakthrough Therapy Designation in 2015 for the desensitization of peanut-allergic patients 4 to 17 years of age.
The European Medicines Agency is reviewing Aimmune's Marketing Authorization Application for Palforzia, which Aimmune submitted in June 2019.
Aimmune initiated a randomised phase 2 clinical trial of its second investigational, complex biologic product, AR201, for the treatment of egg allergy in August 2019.
Inimmune signs research collaboration with Boston Children's Hospital
ResVita Bio receives USD250,000 phase one Small Business Innovation Research grant from NIAID
Phase II Data of Oral Dexpramipexole Published in Eosinophilic Asthma
AllerVie Health Rebrands Southern Allergy & Asthma
Applied BioCode Inks Distribution Agreement with Medline Industries
Vedanta Biosciences Receives Fast Track Designation for VE303
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop
French Ophthalmology Specialist Horus Pharma Group Launches a Nordic Subsidiary